CSL Limited, founded in 1916 as the Commonwealth Serum Laboratories, has evolved from a government-owned vaccine and serum producer into a global biopharmaceutical leader, known for plasma-derived therapies, vaccines, and innovations in immunology. Key milestones include the development of human insulin, the privatization in 1994, the acquisition of Aventis Behring in 2004, and its inclusion in the Forbes Global 2000.
The Commonwealth Serum Laboratories (CSL) is established by the Australian government to produce vaccines and sera for public health needs, particularly addressing the threat of infectious diseases. #history #biotech
CSL begins producing antivenoms for snake and spider bites, becoming a world leader in antivenom research and production. #medicine #biotech
CSL develops and produces diphtheria antitoxin, significantly reducing diphtheria mortality in Australia. #vaccines #publichealth
CSL becomes one of the first institutions in the world to manufacture penicillin, playing a critical role in the Allied war effort during WWII. #medicine #wwii
CSL begins research into polio vaccines, later producing Salk and Sabin vaccines that help eradicate polio in Australia. #vaccines #publichealth
CSL becomes the first Australian manufacturer of insulin, using bovine and porcine sources to treat diabetes. #diabetes #medicine
CSL develops and produces a measles vaccine, contributing to global immunization efforts. #vaccines #pediatrics
CSL expands into plasma fractionation, establishing a blood products division to produce albumin, immunoglobulins, and clotting factors. #plasma #biotech
CSL introduces a hepatitis B vaccine, becoming a key supplier in Australia and overseas. #vaccines #hepatitis
CSL launches recombinant human insulin, produced via genetically modified bacteria, ending reliance on animal-derived insulin. #biotech #diabetes
CSL develops a cytomegalovirus-specific immunoglobulin for immunocompromised patients. #immunology #biotech
The Australian government sells CSL via a public float on the Australian Securities Exchange, raising A$500 million and transforming it into a for-profit company. #finance #privatization
Brian McNamee becomes CEO, leading CSL through a period of rapid growth and global expansion. #leadership #corporate
CSL introduces its seasonal influenza vaccine, Fluvax, which becomes a major product. #vaccines #flu
CSL acquires Rhein Biotech, a German biotech firm, expanding its vaccine and recombinant protein capabilities in Europe. #mergers #acquisitions
CSL opens its first plasma collection centers in the United States, laying the foundation for CSL Plasma network. #plasma #expansion
CSL acquires the plasma therapeutics business of Aventis Behring for €925 million, becoming the world's largest plasma fractionator. #mergers #global
CSL launches Hizentra, a 20% subcutaneous immunoglobulin for primary immunodeficiency, offering a convenient home-use therapy. #immunology #biotech
CSL establishes a presence in China, partnering with local firms to supply plasma products. #global #asia
CSL is added to the S&P/ASX 20 index, reflecting its status as one of Australia's largest listed companies. #finance #index
CSL produces the Panvax H1N1 vaccine in response to the swine flu pandemic, demonstrating rapid response capabilities. #pandemic #vaccines
CSL launches Privigen, a 10% liquid intravenous immunoglobulin for chronic immune thrombocytopenic purpura (ITP). #immunology #biotech
CSL acquires a plasma-derived alpha-1 antitrypsin product from Kamada, strengthening its respiratory portfolio. #respiratory #biotech
CSL receives FDA approval for Haegarda, a subcutaneous C1 esterase inhibitor for hereditary angioedema. #immunology #FDA
CSL launches Afstyla, a recombinant single-chain factor VIII with extended half-life for hemophilia A. #hemophilia #biotech
CSL collaborates with the University of Queensland to develop new vaccine technologies, including a chimeric vaccine platform. #vaccines #partnership
CSL marks its 100th anniversary with record revenue of over A$6 billion, driven by strong plasma product sales. #anniversary #finance
CSL acquires the influenza vaccine business of Novartis for $275 million, gaining access to the Flucelvax cell-culture vaccine. #acquisitions #vaccines
CSL Behring launches Kcentra, a 4-factor prothrombin complex concentrate for reversal of warfarin anticoagulation. #hematology #biotech
Paul Perreault succeeds Brian McNamee as CEO, continuing CSL's growth strategy. #leadership #corporate
CSL's caplacizumab (Cablivi) receives FDA approval for acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. #hematology #FDA
CSL enters into an agreement to manufacture the AstraZeneca COVID-19 vaccine for Australia and the region. #COVID19 #partnership
CSL partners with University of Queensland on a COVID-19 vaccine candidate (V451), but it is discontinued after false positive HIV test interference. #COVID19 #vaccines
CSL Seqirus launches its cell-based quadrivalent influenza vaccine (Flucelvax) in Japan, expanding its global footprint. #vaccines #global
Suzanne R. Rogers is appointed Chair of CSL Limited, succeeding Brian McNamee. #leadership #diversity
CSL completes the acquisition of Vifor Pharma for $11.7 billion, adding iron deficiency and nephrology treatments to its portfolio. #acquisitions #pharma
CSL reports annual revenue exceeding A$15 billion for the first time, driven by strong plasma product sales and Vifor contributions. #finance #revenue
CSL Behring launches Hemgenix, the first gene therapy for hemophilia B approved in the US, offering a potential one-time cure. #genetherapy #hemophilia
CSL's garadacimab, a monoclonal antibody for hereditary angioedema prophylaxis, receives FDA approval. #immunology #FDA
CSL Plasma expands into Europe, opening new collection centers in Germany and Switzerland. #plasma #expansion